Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells.

Autor: Ogata K; Metropolitan Research and Treatment Center for Blood Disorders (MRTC Japan), Tokyo, Japan. Electronic address: ogata@MRCJAPAN.com., Sei K; Metropolitan Research and Treatment Center for Blood Disorders (MRTC Japan), Tokyo, Japan., Saft L; Department of Clinical Pathology, Division of Hematopathology, Karolinska University Hospital and Institute, Solna, Stockholm, Sweden., Kawahara N; Metropolitan Research and Treatment Center for Blood Disorders (MRTC Japan), Tokyo, Japan., Porta MGD; Cancer Center, Humanitas Research Hospital and Humanitas University, Rozzano, Milan, Italy., Chapuis N; Institut Cochin, INSERM U1016, CNRS UMR8104, Université Paris Descartes, France; Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie Biologique, Paris, France., Yamamoto Y; Metropolitan Research and Treatment Center for Blood Disorders (MRTC Japan), Tokyo, Japan.
Jazyk: angličtina
Zdroj: Leukemia research [Leuk Res] 2018 Aug; Vol. 71, pp. 75-81. Date of Electronic Publication: 2018 Jul 10.
DOI: 10.1016/j.leukres.2018.07.009
Abstrakt: Diagnosis of myelodysplastic syndromes (MDS) is not straightforward when objective data, such as blast excess and abnormal cytogenetics, are lacking. Expert laboratories use flow cytometry (FCM) to help diagnose MDS. However, most of FCM protocols for MDS are complex, requiring a high level of expertise and high cost. We have reported a FCM mini-panel consisting of four FCM parameters (so-called Ogata score), which is simple to conduct and inexpensive. In this paper, to refine this mini-panel, we have introduced a new FCM parameter, which quantifies CD33 expression on CD34+ cells (called Granulocyte/CD34 cell CD33 ratio). Bone marrow cells from MDS without blast excess (low-grade MDS) and controls were stained with CD34, CD45, and CD33 and analyzed for five parameters ("Granulocyte/CD34 cell CD33 ratio" plus four parameters in the Ogata score). By a multivariate logistic regression model, only three parameters, including "Granulocyte/CD34 cell CD33 ratio" had statistically significant power for diagnosing low-grade MDS. Based on the results, we constructed a new scoring system, which showed approximately 50% sensitivity and more than 95% specificity in diagnosing low-grade MDS. Our revised mini-panel is suitable for screening samples suspected for MDS and provides a basis for further improvement in diagnostic FCM protocols for MDS.
(Copyright © 2018 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: